In my experience, it’s difficult to get or stay well while on medication. I have a hard time taking it, but I’ve always struggled to go about my life like I was yesterday.
I was diagnosed with Schizophrenia in 2008, and I’ve been taking Seroquel since, with the exception of two years. I don’t see how Seroquel can change my life. I don’t want to lose it, but I’m not ready to take the leap yet.
Seroquel has helped me with the symptoms of schizophrenia, but I haven’t yet noticed that it is working as well as it used to. It’s been about 4 years, and I’m still working on it.
My doctor suggested that I try Seroquel for a few weeks before I head to the ER to get my medication, and that’s it! I’ve never tried it before, so I don’t know if this is the best option or not.
There’s a good reason for this. Seroquel is used for schizophrenia, so you don’t want to get out of bed and have to deal with withdrawal symptoms when you start taking it.
I think I’m just not good at dealing with the symptoms I’m dealing with. When you start to get psychotic symptoms, you want to feel like you are going through a process, like you don’t know what is going to happen. But if you feel like you have symptoms, you can come in and sit back and watch it go through its own process. I’ve been trying Seroquel for years, but it’s been very difficult.
I’ve been on Seroquel for years, and I know I can do the job for the rest of my life. I feel like I need it for a little while, and then I start seeing what happens.
There is no “bad” side effect. I’ve tried Seroquel a few times in the past, and it has helped. I’m glad I’m not alone with that.
My symptoms are just getting worse, and I’m not even sure I can take it anymore. The last couple of months have been a struggle, and I’ve been trying to put it all out there. I’ve been taking Seroquel twice, and I can feel a lot of weight gain in the weeks after the first pill, but I have gained a bit of weight in the weeks after the second pill. I don’t have any physical problems at this time, but I think I’ll be okay.
I’ve been on the Seroquel regimen for three months now, and I don’t see any signs of my symptoms getting better. I just feel like I’m not really going to be taking the drug.
I’ve tried everything, and I’ve been very frustrated by the symptoms I’ve experienced. My doctor said to stop the medication, and I thought that was not going to work for me.
I just can’t get it up. I’ve been struggling with the side effects of Seroquel, and the thought of having to get a prescription filled while on this medication makes me anxious. I’ve had to do it a lot, but it hasn’t done anything for me.
If I could have the life I want, I could have the life I want.
I’m not the kind of person that just needs to give up on me. I’m so much more than I was the other day. I’m not that ready for that kind of life, and I’m not ready to be ready to do anything right now.
—Travis
|Posted on July 4, 2023 by
by
It’s been a rough year, but I started feeling very anxious. I was having trouble sleeping, and I was also seeing my doctor. I started taking Seroquel and the first night I went to the ER, I was having trouble sleeping. I felt like I was having a panic attack, like I couldn’t sleep anymore. It was just so intense.
The next night I woke up and started having thoughts of suicide. I’d been having a lot of anxiety since, and I was worried that I’d just become suicidal.
Seroquel XR, also known as quetiapine fumarate, is an atypical antipsychotic medication used in the treatment of various mental health disorders, including schizophrenia, bipolar disorder, and major depressive disorder. The drug is marketed by AstraZeneca and has been a significant player in the pharmaceutical market due to its broad therapeutic applications.
Seroquel XR has a a global market for its product. It is anticipated to experience steady growth. As of 2024, the company's product market is estimated to be about USD 30.22 billion.
The global Seroquel XR product market for 2024-2031 wasasures at which combinations of Seroquel XR and other medications were classified as Tier 1 or Tier 2 drugs, such as:
The Seroquel XR product market for 2024-2031 has been steadily growing, reaching a revenue value of USD 30.24 billion, growing at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2030. It is projected to reach a value of USD 38.6 billion in 2030, growing at a CAGR of 3.3% during the same period.
The Seroquel XR product market for adults was valued at USD 30.22 billion in 2024 and is expected to reach USD 38.6 billion in 25 years, growing at a CAGR of 3.3% from 2024 to 30%. The global Seroquel XR product market is expected to reach USD 37.1 billion by 2030, growing at a CAGR of 3.2% during the same period.
The Seroquel XR product market for children is estimated to be about USD 3.1 billion in 25 years and is projected to reach USD 5.0 billion in 25 years, growing at a CAGR of 2.5% from 2024 to 2030. The market is expected to reach around USD 5.5 billion in 25 years.
The safety of Seroquel for the children of AstraZeneca's patients has been studied in several clinical trials and has been used as a reliable secondary analysis of existing data. As of early 2023, Seroquel has been approved for the paediatric population for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. However, its safety for the children of AstraZeneca's patients has not been evaluated in children under the age of four. Secondary analysis of data from a controlled clinical trial has shown that children aged 4 to 17 have a 3.5 times higher risk of death from any cause when they receive Seroquel XR compared to children under the age of four. The trial showed that Seroquel XR patients were more likely to develop serotonin syndrome, a potentially life-threatening condition characterized by seizures, agitation, and abnormal muscle activity in children.
The Seroquel drug market was valued at USD 5.1 billion in 2023 and is expected to reach USD 9.8 billion by 2529. It is valued at USD 4.8 billion in 2024 and is expected to grow at a CAGR of 1.8% from 2024 to 3009. The company's currently available generic versions of Seroquel have shown promising growth over the past few years.
The Seroquel market is driven by the growth of the Seroquel product portfolio and the increasing prevalence of side effects associated with Seroquel. A major player in the Seroquel drug product market is AstraZeneca's healthcare business, which saw Seroquel market increase at a CAGR of 3.2% from 2024 to 3024.
A recent study published in the British Medical Journal (BMJ) confirmed the association between SEROQUEL (quetiapine fumarate extended release tablet) and cardiovascular disease (CVD). The study, reported in the British Medical Journal, investigated the association between SEROQUEL (quetiapine fumarate extended release tablet) and the risk of CVD. The study included a total of 4,851 patients with primary or secondary CVD (n=8,122), with or without previous CVD (n=9,232) and healthy controls (n=6,072). Patients were aged between 40 and 60 years (mean age 61.6 years) and had at least one diagnosis of CVD (defined as CVD in at least six years of follow up) according to the Global Burden of Disease (2023) guidelines.
The study examined the risk of developing CVD in patients with primary or secondary CVD (n=4,979) who were prescribed SEROQUEL (quetiapine fumarate extended release tablet) for 3 years, at a dose of 300 mg per day. The authors found a significant increase in risk of CVD, with adjusted incidence rates for each of the three main groups. The adjusted odds ratio for developing CVD increased by 1.7 times that of the general population (adjusted hazard ratio 1.7, 95% confidence interval 1.5 to 1.9, p=0.01).
The authors also observed that patients who had a history of CVD had a significantly increased risk of developing a new CVD. The authors concluded that patients who have previously had CVD should have a lower risk of developing new CVD compared to those with no previous history of CVD.
“This study confirms the findings of previous studies, showing that SEROQUEL (quetiapine fumarate extended release tablet) has a very similar protective effect against the development of CVD in patients with primary or secondary CVD. The risk of developing CVD in patients taking SEROQUEL (quetiapine fumarate extended release tablet) is also lower than that observed in patients with other antidepressants,” the authors write.
Source:
Dr Andrew StewartRead moreA recent study published in the British Medical Journal confirmed the association between SEROQUEL (quetiapine fumarate extended release tablet) and the risk of CVD. The study, reported in the British Medical Journal, investigated the association between the risk of developing CVD and SEROQUEL (quetiapine fumarate extended release tablet) in a sample of patients with primary or secondary CVD. The authors found a significant increase in risk of developing CVD, with adjusted incidence rates for each of the three main groups.
The authors also observed that patients who had previously had CVD had a significantly increased risk of developing a new CVD.
The researchers concluded that patients who have previously had CVD should have a lower risk of developing a new CVD compared to those with no previous history of CVD. The authors also recommended that patients who have previously had CVD should have a lower risk of developing a new CVD compared to those with no previous history of CVD.
The authors of the study included a sample of 8,122 patients with primary or secondary CVD and had at least one diagnosis of CVD according to the global Burden of Disease (2023) guidelines. The researchers conducted a total of 4,849 case-control visits for patients with primary or secondary CVD and 7,232 controls for patients with no previous CVD. They found a significant association between SEROQUEL (quetiapine fumarate extended release tablet) use and the risk of CVD, with adjusted incidence rates for each of the three main groups.
AstraZeneca today announced that the European Medicines Agency’s guidance for the management of schizophrenia (S) and the use of Seroquel has been approved. The approval of Seroquel in Europe is expected to result in the first approval of its generic status in the United States.
“This approval is a critical step in our strategy to bring Seroquel to the US market. We will continue to evaluate the clinical development and efficacy data to determine the best treatment option for the patient,” said Dr. Peter Dunn, Chairman and Chief Executive Officer of AstraZeneca.
“We are pleased to have been granted the opportunity to move forward with our strategy in Europe and to collaborate with our partners to make a substantial impact in the United States.”
In addition, AstraZeneca has agreed to provide a further six months of data to determine the appropriate therapeutic dosage for Seroquel in the US market.
“In the meantime, we are actively reviewing the decision-making process and our management team is committed to providing the most comprehensive care available to patients,” stated Dr. Alan Greensl liabilities.
“In the meantime, we are pleased to announce the approval of Seroquel as the first generic of an existing brand of Seroquel approved in the United States. AstraZeneca is in the process of evaluating its generic status and is currently working to complete the necessary approval process in the United States.”
The decision-making process for Seroquel is complex, involving extensive clinical data, regulatory submissions, and the use of new, innovative technologies.
“We are pleased to have been granted an opportunity to move forward with our strategy in Europe and to collaborate with our partners to make a substantial impact in the United States,” said Dr.
“We look forward to working closely with our partners to ensure the next important step in the management of patients who may not be suitable candidates for Seroquel,” stated Dr.
In addition, AstraZeneca has agreed to provide a further six months of data to determine the appropriate therapeutic dosage for Seroquel in the United States.
“We are pleased to have been granted an opportunity to move forward with our strategy in Europe and to collaborate with our partners to make a substantial impact in the United States,” stated Dr.
“We look forward to working closely with our partners to ensure the next important step in the management of patients who may not be suitable candidates for Seroquel,” said Dr.
“In the meantime, we are pleased to announce the approval of Seroquel as the first generic of an existing brand of Seroquel approved in the United States.”
“In the meantime, we are pleased to have been granted an opportunity to move forward with our strategy in Europe and to collaborate with our partners to make a substantial impact in the United States,” stated Dr.
“In the meantime, we are pleased to have been granted an opportunity to move forward with our strategy in Europe and to collaborate with our partners to make a substantial impact in the United States,” said Dr.
Stade de France Pharmacy